TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $630.76M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alaunos Therapeutics USD 2.68M 1.05M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Ardelyx USD 382.32M 14.33M Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Bayer EUR 32.91B 30M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Corcept Therapeutics USD 485.46M 55.67M Dec/2025
Curis USD 6.92M 7.5M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
TG Therapeutics USD 630.76M 31M Dec/2025
Verastem USD 223.41M 69.36M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025